Onkologie. 2016:10(1):7-10 | DOI: 10.36290/xon.2016.003

Molecular profiling of lung cancer

Marek Minárik^1,2

¹ Centrum aplikované genomiky solidních nádorů (CEGES), Genomac výzkumný ústav, s.r.o., Praha

² Interní klinika 1. LF UK a ÚVN VFN Praha

As in other solid tumours, the development and progression of lung cancer is accompanied by a whole number of genome disorders

(mutations). These often characteristic disorders represent molecular markers and their investigation has now become an inseparable

part of the diagnostic-therapeutic process. Supplementing the conventional morphology-based histopathological classification with

information on the molecular profile is becoming a completely crucial tool for predicting the success rate of anticancer treatment as

well as estimating the prognosis of cancer patients. A new trend in modern pathological diagnosis is the method of so-called liquid

biopsy, or the investigation of cancer cells and tumour DNA released into the patient’s peripheral circulation.

Keywords: lung cancer, NSCLC, SCLC, liquid biopsy, CTC, ctDNA

Published: March 1, 2016  Show citation